New treatment approach for Alzheimer's disease using VGF delivery to the brain
Therapeutic Strategy to Treat Alzheimer's Disease by VGF Delivery into Brain
This study is testing a new gene therapy for Alzheimer's disease that delivers a special protein directly into the brain using tiny particles, and it’s designed to help improve memory and thinking skills for people living with this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | North Dakota State University NIH-funded |
| Lab location | 1 site (Fargo, United States) |
| Project ID | NIH-11088177 on NIH RePORTER |
What this research studies
This research focuses on developing a novel gene therapy for Alzheimer's disease by delivering a protein called VGF directly into the brain. The approach involves creating specialized nanoparticles that can safely cross the blood-brain barrier and target brain cells. By using both intravenous and intranasal methods for administration, the therapy aims to enhance neuron growth and survival, potentially improving cognitive functions affected by Alzheimer's. Patients may be monitored for changes in memory and cognitive abilities as part of the treatment process.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Alzheimer's disease or those experiencing significant cognitive decline associated with aging.
Not a fit: Patients with early-stage Alzheimer's or those without cognitive impairment may not receive direct benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to a groundbreaking treatment that improves cognitive function and slows the progression of Alzheimer's disease.
How similar studies have performed: While gene therapy for Alzheimer's is a relatively novel approach, preliminary studies have shown promise in similar methodologies, indicating potential for success.
Where this research is happening
Fargo, United States
- North Dakota State University — Fargo, United States (Active)
Researchers
- Principal investigator: Singh, Jagdish — North Dakota State University
- Study coordinator: Singh, Jagdish
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.